Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to addr ...

Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) has been assigned an average rating of “Buy” from the twenty analysts that are currently covering the stock, MarketBeat reports. Twenty analysts ...

Chlamydia vaccine candidate granted fast track designation by the US FDAChlamydia infection can contribute to pelvic inflammatory diseases in ...

Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infer ...

The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...

Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) ...

The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral ...

Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.

The CDC has rescheduled a key advisory committee meeting on vaccine experts to April following a delay in February, a week ...